Consensus Simulations Plus, Inc.

Stocks

SLP

US8292141053

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 00:00:00 15/09/2026 +04			5-day change	1st Jan Change
18.42 ^USD	0.00%		-0.05%	+1.04%

08-20	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
07-10	Simulations Plus Fiscal Q3 Adjusted Earnings Decline, Revenue Rises	MT

Evolution of the Average Target: Simulations Plus, Inc.

Evolution of the Target Price: Simulations Plus, Inc.

Changes in Analyst Recommendations: Simulations Plus, Inc.

2878c9b6d15600.7WpznkEl9VjQFEzqkrlep-6efKhrcGqQ88kAEKmPST4.rDBeqXNVrxP9fBqA2M4w_5TwI5FYBTPRnLxsYvy9HQvULjGmAkfCIZwteA~ca1e729b7744224a92d277ce36af2f39

Analysts' recommendations: Simulations Plus, Inc.

06-18	Craig-Hallum Downgrades Simulations Plus to Hold From Buy, Adjusts Price Target to $18.50 From $31	MT
06-17	William Blair Downgrades Simulations Plus to Market Perform From Outperform	MT
12-18	BTIG Research Downgrades Simulations Plus to Neutral From Buy	MT
30/09/25	TD Cowen Initiates Simulations Plus at Hold With $16 Price Target	MT
15/07/25	KeyBanc Downgrades Simulations Plus to Sector Weight From Overweight, Removes $25 Price Target	MT
07/07/25	BTIG Adjusts Price Target on Simulations Plus to $25 From $41, Maintains Buy Rating	MT
08/01/25	KeyBanc Lowers Price Target on Simulations Plus to $35 From $40, Keeps Overweight Rating	MT
15/11/24	Stephens Initiates Simulations Plus at Overweight With $39 Price Target	MT
29/07/24	KeyBanc Initiates Simulations Plus at Overweight With $47 Price Target	MT
16/07/24	JMP Securities Initiates Simulations Plus at Market Perform	MT
03/07/24	Top Decliners	MT
28/06/24	William Blair Initiates Simulations Plus at Outperform	MT
13/06/24	Craig-Hallum Raises Price Target on Simulations Plus to $56 From $51, Maintains Buy Rating	MT
13/06/24	Oppenheimer Adjusts Price Target on Simulations Plus to $65 From $55, Maintains Outperform Rating	MT
26/10/23	Oppenheimer Adjusts Simulations Plus Price Target to $55 From $67, Maintains Outperform Rating	MT
21/06/23	Oppenheimer Raises Simulations' Plus Price Target to $67 From $65, Maintains Outperform Rating	MT
09/05/23	BTIG Initiates Simulations Plus at Buy With $55 Price Target	MT
22/12/22	Sidoti Cuts Price Target on Simulations Plus to $44 From $56, Keeps Neutral Rating	MT
27/10/22	Oppenheimer Adjusts Simulations Plus Price Target to $65 From $75, Maintains Outperform Rating	MT
29/08/22	Raymond James Adjusts Price Target on Simulations Plus to $70 From $54, Keeps Outperform Rating	MT
26/08/22	Raymond James Adjusts Simulations Plus Price Target to $70 From $54, Maintains Outperform Rating	MT
07/07/22	Craig Hallum Raises Simulations Plus' Price Target to $60 From $55, Buy Rating Kept	MT
26/10/21	Craig-Hallum Upgrades Simulations Plus to Buy From Hold; Price Target is $53	MT
13/07/21	Simulations Plus : Oppenheimer Adjusts Simulations Plus PT to $75 From $85 Following Fiscal Q3 Miss, Maintains Outperform Rating	MT
13/07/21	Simulations Plus : Craig-Hallum Adjusts Price Target on Simulations Plus to $65 From $74, Maintains Hold Rating	MT

More recommendations

Medical Software & Technology Services

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
SIMULATIONS PLUS, INC.	-			-6.35%
VEEVA SYSTEMS INC.				+13.3%
PRO MEDICUS LIMITED				+23.2%
SECTRA AB				+18.88%
HEARTFLOW, INC.				-10.23%
GENERATE BIOMEDICINES, INC.				+71.76%
OMNICELL, INC.				+76.45%
XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.		-		+58.63%
ARBUTUS BIOPHARMA CORPORATION		-	-	+7.42%
Average				+28.12%
Weighted average by Cap.				+17.51%